🇺🇸 FDA
Pipeline program

EMPAGLIFLOZIN, Placebo matching BI 690517, BI 690517

1378-0020

Phase 3 small_molecule active

Quick answer

EMPAGLIFLOZIN, Placebo matching BI 690517, BI 690517 for Heart failure (HF) is a Phase 3 program (small_molecule) at Boehringer Ingelheim International GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Boehringer Ingelheim International GmbH
Indication
Heart failure (HF)
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials